Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro
E Lindhagen, L Rickardson, G Elliott, L Leoni… - Investigational new …, 2007 - Springer
Summary SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-
etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their …
etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their …
R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary …
E Lindhagen, S Nissle, L Leoni, G Elliott… - Cancer chemotherapy …, 2007 - Springer
Objective SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid
anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic …
anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic …
SDX‐308 and SDX‐101, non‐steroidal anti‐inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma
S Lentzsch, G Elliott… - Archiv der Pharmazie: An …, 2007 - Wiley Online Library
Non‐steroidal anti‐inflammatory drugs have been shown to inhibit carcinogenesis in colon
cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti‐tumor effects are …
cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti‐tumor effects are …
Quantitative Structural Activity Relationship Studies for In Silico Prediction of In Vitro Cytotoxicity of NSAIDs in Colon Cancer Cell Lines
Non-steroidal anti-inflammatory drugs (NSAIDs) are evolving as the prototypical
chemopreventive agents against colon cancer, an opinion nowadays reinforced by a …
chemopreventive agents against colon cancer, an opinion nowadays reinforced by a …